Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment

Kathleen M. Daddario-DiCaprio, Thomas Geisbert, Ute Ströher, Joan B. Geisbert, Allen Grolla, Elizabeth A. Fritz, Lisa Fernando, Elliott Kagan, Peter B. Jahrling, Lisa E. Hensley, Steven M. Jones, Heinz Feldmann

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Background: Effective countermeasures are urgently needed to prevent and treat infections caused by highly pathogenic and biological threat agents such as Marburg virus (MARV). We aimed to test the efficacy of a replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever. Methods: We used a rhesus macaque model of MARV haemorrhagic fever that produced 100% lethality. We administered rVSV vectors expressing the MARV Musoke strain glycoprotein to five macaques 20-30 min after a high-dose lethal injection of homologous MARV. Three animals were MARV-positive controls and received non-specific rVSV vectors. We tested for viraemia, undertook analyses for haematology and serum biochemistry, and measured humoral and cellular immune responses. Findings: All five rhesus monkeys that were treated with the rVSV MARV vectors as a postexposure treatment survived a high-dose lethal challenge of MARV for at least 80 days. None of these five animals developed clinical symptoms consistent with MARV haemorrhagic fever. All the control animals developed fulminant disease and succumbed to the MARV challenge by day 12. MARV disease in the controls was indicated by: high titres of MARV (103-105 plaque-forming units per mL); development of leucocytosis with concurrent neutrophilia at end-stage disease; and possible damage to the liver, kidney, and pancreas. Interpretation: Postexposure protection against MARV in non-human primates provides a paradigm for the treatment of MARV haemorrhagic fever. Indeed, these data suggest that rVSV-based filoviral vaccines might not only have potential as preventive vaccines, but also could be equally useful for postexposure treatment of filoviral infections.

Original languageEnglish (US)
Pages (from-to)1399-1404
Number of pages6
JournalLancet
Volume367
Issue number9520
DOIs
StatePublished - Apr 29 2006
Externally publishedYes

Fingerprint

Marburg Virus Disease
Marburgvirus
Vesicular Stomatitis
Primates
Viruses
Vaccines
Macaca mulatta
Capital Punishment
Viremia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates : an efficacy assessment. / Daddario-DiCaprio, Kathleen M.; Geisbert, Thomas; Ströher, Ute; Geisbert, Joan B.; Grolla, Allen; Fritz, Elizabeth A.; Fernando, Lisa; Kagan, Elliott; Jahrling, Peter B.; Hensley, Lisa E.; Jones, Steven M.; Feldmann, Heinz.

In: Lancet, Vol. 367, No. 9520, 29.04.2006, p. 1399-1404.

Research output: Contribution to journalArticle

Daddario-DiCaprio, KM, Geisbert, T, Ströher, U, Geisbert, JB, Grolla, A, Fritz, EA, Fernando, L, Kagan, E, Jahrling, PB, Hensley, LE, Jones, SM & Feldmann, H 2006, 'Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment', Lancet, vol. 367, no. 9520, pp. 1399-1404. https://doi.org/10.1016/S0140-6736(06)68546-2
Daddario-DiCaprio, Kathleen M. ; Geisbert, Thomas ; Ströher, Ute ; Geisbert, Joan B. ; Grolla, Allen ; Fritz, Elizabeth A. ; Fernando, Lisa ; Kagan, Elliott ; Jahrling, Peter B. ; Hensley, Lisa E. ; Jones, Steven M. ; Feldmann, Heinz. / Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates : an efficacy assessment. In: Lancet. 2006 ; Vol. 367, No. 9520. pp. 1399-1404.
@article{8fadb4f3fd324e179974f301d37e563f,
title = "Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment",
abstract = "Background: Effective countermeasures are urgently needed to prevent and treat infections caused by highly pathogenic and biological threat agents such as Marburg virus (MARV). We aimed to test the efficacy of a replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever. Methods: We used a rhesus macaque model of MARV haemorrhagic fever that produced 100{\%} lethality. We administered rVSV vectors expressing the MARV Musoke strain glycoprotein to five macaques 20-30 min after a high-dose lethal injection of homologous MARV. Three animals were MARV-positive controls and received non-specific rVSV vectors. We tested for viraemia, undertook analyses for haematology and serum biochemistry, and measured humoral and cellular immune responses. Findings: All five rhesus monkeys that were treated with the rVSV MARV vectors as a postexposure treatment survived a high-dose lethal challenge of MARV for at least 80 days. None of these five animals developed clinical symptoms consistent with MARV haemorrhagic fever. All the control animals developed fulminant disease and succumbed to the MARV challenge by day 12. MARV disease in the controls was indicated by: high titres of MARV (103-105 plaque-forming units per mL); development of leucocytosis with concurrent neutrophilia at end-stage disease; and possible damage to the liver, kidney, and pancreas. Interpretation: Postexposure protection against MARV in non-human primates provides a paradigm for the treatment of MARV haemorrhagic fever. Indeed, these data suggest that rVSV-based filoviral vaccines might not only have potential as preventive vaccines, but also could be equally useful for postexposure treatment of filoviral infections.",
author = "Daddario-DiCaprio, {Kathleen M.} and Thomas Geisbert and Ute Str{\"o}her and Geisbert, {Joan B.} and Allen Grolla and Fritz, {Elizabeth A.} and Lisa Fernando and Elliott Kagan and Jahrling, {Peter B.} and Hensley, {Lisa E.} and Jones, {Steven M.} and Heinz Feldmann",
year = "2006",
month = "4",
day = "29",
doi = "10.1016/S0140-6736(06)68546-2",
language = "English (US)",
volume = "367",
pages = "1399--1404",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9520",

}

TY - JOUR

T1 - Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates

T2 - an efficacy assessment

AU - Daddario-DiCaprio, Kathleen M.

AU - Geisbert, Thomas

AU - Ströher, Ute

AU - Geisbert, Joan B.

AU - Grolla, Allen

AU - Fritz, Elizabeth A.

AU - Fernando, Lisa

AU - Kagan, Elliott

AU - Jahrling, Peter B.

AU - Hensley, Lisa E.

AU - Jones, Steven M.

AU - Feldmann, Heinz

PY - 2006/4/29

Y1 - 2006/4/29

N2 - Background: Effective countermeasures are urgently needed to prevent and treat infections caused by highly pathogenic and biological threat agents such as Marburg virus (MARV). We aimed to test the efficacy of a replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever. Methods: We used a rhesus macaque model of MARV haemorrhagic fever that produced 100% lethality. We administered rVSV vectors expressing the MARV Musoke strain glycoprotein to five macaques 20-30 min after a high-dose lethal injection of homologous MARV. Three animals were MARV-positive controls and received non-specific rVSV vectors. We tested for viraemia, undertook analyses for haematology and serum biochemistry, and measured humoral and cellular immune responses. Findings: All five rhesus monkeys that were treated with the rVSV MARV vectors as a postexposure treatment survived a high-dose lethal challenge of MARV for at least 80 days. None of these five animals developed clinical symptoms consistent with MARV haemorrhagic fever. All the control animals developed fulminant disease and succumbed to the MARV challenge by day 12. MARV disease in the controls was indicated by: high titres of MARV (103-105 plaque-forming units per mL); development of leucocytosis with concurrent neutrophilia at end-stage disease; and possible damage to the liver, kidney, and pancreas. Interpretation: Postexposure protection against MARV in non-human primates provides a paradigm for the treatment of MARV haemorrhagic fever. Indeed, these data suggest that rVSV-based filoviral vaccines might not only have potential as preventive vaccines, but also could be equally useful for postexposure treatment of filoviral infections.

AB - Background: Effective countermeasures are urgently needed to prevent and treat infections caused by highly pathogenic and biological threat agents such as Marburg virus (MARV). We aimed to test the efficacy of a replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever. Methods: We used a rhesus macaque model of MARV haemorrhagic fever that produced 100% lethality. We administered rVSV vectors expressing the MARV Musoke strain glycoprotein to five macaques 20-30 min after a high-dose lethal injection of homologous MARV. Three animals were MARV-positive controls and received non-specific rVSV vectors. We tested for viraemia, undertook analyses for haematology and serum biochemistry, and measured humoral and cellular immune responses. Findings: All five rhesus monkeys that were treated with the rVSV MARV vectors as a postexposure treatment survived a high-dose lethal challenge of MARV for at least 80 days. None of these five animals developed clinical symptoms consistent with MARV haemorrhagic fever. All the control animals developed fulminant disease and succumbed to the MARV challenge by day 12. MARV disease in the controls was indicated by: high titres of MARV (103-105 plaque-forming units per mL); development of leucocytosis with concurrent neutrophilia at end-stage disease; and possible damage to the liver, kidney, and pancreas. Interpretation: Postexposure protection against MARV in non-human primates provides a paradigm for the treatment of MARV haemorrhagic fever. Indeed, these data suggest that rVSV-based filoviral vaccines might not only have potential as preventive vaccines, but also could be equally useful for postexposure treatment of filoviral infections.

UR - http://www.scopus.com/inward/record.url?scp=33646135089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646135089&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(06)68546-2

DO - 10.1016/S0140-6736(06)68546-2

M3 - Article

C2 - 16650649

AN - SCOPUS:33646135089

VL - 367

SP - 1399

EP - 1404

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9520

ER -